Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Trifluoperazine hydrochloride
Drug ID BADD_D02282
Description A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic.
Indications and Usage For the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation.
Marketing Status approved; investigational
ATC Code N05AB06
DrugBank ID DB00831
KEGG ID D00799
MeSH ID D014268
PubChem ID 66064
TTD Drug ID D0R4OM
NDC Product Code 0781-8032; 51079-572; 0378-2410; 51079-573; 0378-2405; 0781-8034; 46204-0081; 0781-8028; 0781-8036; 70518-2095; 51079-574; 0378-2402; 51079-575; 0378-2401; 70518-2106
UNII 6P1Y2SNF5V
Synonyms Trifluoperazine | Trifluperazine | Trifluoroperazine | Eskazine | Flupazine | Terfluzine | Trifluoperazine Hydrochloride | Trifluoperazine HCL | Triftazin | Apo-Trifluoperazine | Apo Trifluoperazine | ApoTrifluoperazine | Stelazine
Chemical Information
Molecular Formula C21H26Cl2F3N3S
CAS Registry Number 440-17-5
SMILES CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F.Cl.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agitation17.02.05.012; 19.06.02.001--
Agranulocytosis01.02.03.001---
Akathisia17.01.02.002; 19.06.02.006--
Amenorrhoea05.05.01.002; 21.01.02.001--
Anaphylactoid reaction10.01.07.003; 24.06.03.007---
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Anticholinergic syndrome17.05.01.001---
Aplastic anaemia01.03.03.002---
Asphyxia12.01.08.011; 22.02.02.001---
Asthma10.01.03.010; 22.03.01.002---
Cardiac arrest02.03.04.001--
Catatonia19.11.01.001---
Cholestasis09.01.01.001---
Cogwheel rigidity15.05.04.006; 17.01.05.001---
Constipation07.02.02.001--
CSF protein abnormal13.07.02.004---
Dermatitis exfoliative10.01.01.004; 23.03.07.001--
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Drooling17.02.05.005---
Dry mouth07.06.01.002--
Dyskinesia17.01.02.006--
Dysphagia07.01.06.003--
Dyspnoea02.11.05.003; 22.02.01.004--
Eczema23.03.04.006--
Ejaculation disorder21.03.01.002--
Electrocardiogram QT prolonged13.14.05.004--
Endocrine disorder05.09.01.001---
Eosinophilia01.02.04.001--
Epinephrine13.10.01.002---
Erythema23.03.06.001---
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages